Mangoceuticals, Inc. - MGRX STOCK NEWS

Mangoceuticals announced the completion of its first batch of Mango ED oral dissolvable tablets (ODTs) for the Mexican and Latin American markets. These tablets, containing Tadalafil, will undergo tests in the U.S. for quality assurance. The next phase includes producing three additional lots for bioequivalence and stability testing in Mexico to meet COFEPRIS standards. This effort is in collaboration with Emifarma. The ED market in Mexico is valued at $216 million annually, growing at 4% per year. MangoRx aims to expand into other LATAM countries post-COFEPRIS certification.

MangoRx, a company specializing in men’s health and wellness products, announced a partnership with Crakmedia, an international performance marketing company. Crakmedia will spearhead MangoRx's digital marketing initiatives, utilizing their extensive experience in performance marketing, web development, and traffic monetization. Digital ads on Crakmedia's network reach up to 1.5 billion views daily across 150 countries. This collaboration aims to boost MangoRx's sales and market presence significantly. MangoRx will benefit from Crakmedia's 15 years of expertise, AI-driven compliance systems, and industry accolades. This partnership is expected to enhance MangoRx's ability to attract new customers and expand its product portfolio.

MangoRx, a men's health and wellness company, has announced the development of oral formulations of Semaglutide and Tirzepatide, branded as 'Slim' and 'Trim.' These drugs, traditionally available as injectables, are designed to aid in weight management. Clinical trials have shown impressive weight loss results, with Semaglutide yielding a 15.2% weight loss and Tirzepatide 15.7% over one year. The GLP-1 receptor agonists' market is projected to reach $164 billion by 2032. MangoRx's oral versions are expected to capture a significant market share due to patient preference for oral medications. The products will be available on MangoRx's telemedicine platform by Q3 2024, priced at $299/month for 'Slim' and $399/month for 'Trim.'

MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.

Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.

Mangoceuticals, Inc. (NASDAQ: MGRX) acquires a global patent portfolio for a preventive oral solution to combat various infections, expanding into the nutraceutical product space. The patented solution includes unique ingredients like GALALCOOL®️, zinc protoporphyrin IX, and select tannins, offering users a defense against oral and respiratory infections. The acquisition aims to tap into the growing demand for high-quality oral health products, driven by a $25.71 billion market opportunity by 2030. MangoRx plans to commercialize the technology through direct-to-consumer online platforms and retail locations, aligning with its mission to enhance well-being through innovative health solutions.

Mangoceuticals, Inc. (NASDAQ: MGRX) announces a technical agreement with Emifarma S.A. de C.V for the development and testing of Mango ED products for the Mexican and Latin American markets. This marks a significant step towards obtaining certification from COFEPRIS, opening doors for expansion into multiple markets.

Mangoceuticals, Inc. (NASDAQ: MGRX) introduces 'PRIME' by MangoRx, an FDA-approved oral testosterone replacement therapy treatment, targeting men with low testosterone. The company aims to tap into a significant market of men seeking alternative TRT options, leveraging its telehealth platform.

Mangoceuticals, Inc. (NASDAQ: MGRX) launches a direct-to-clinics sales division, allowing doctors to prescribe MangoRx products from their offices. The company aims to increase recurring revenues and reduce customer acquisition costs by deploying a sales force to penetrate men’s health and wellness clinics across the US. The newly developed clinic prescribing system enables practitioners to prescribe MangoRx products, including the recently launched 'PRIME', by MangoRx, powered by Kyzatrex®️.